Sign in
TerminatedNo phase

Resistell Phenotech AST to Determine the Antibiotic Susceptibility of Gram-negative Bacteria Causing Bacteremia

Key facts

Who runs it
Resistell AG
Where
Austria, Spain, and Switzerland3 sites in 3 countriesChoose a country to see its sites
Trial code
Status
Terminated
People taking part
246 people enrolled
Started
18 Jan 2023
Ended
5 Sept 2024
Type of study
Observational
Treatments tested
  • Resistell Phenotech
Record updated
26 October 2024
Why it stopped
Statistical power for primary endpoint (sensitivity) for E. coli and K. pneumoniae and ceftriaxone was achieved

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Patients who have signed a General Consent form approving use of their residual blood samples for research purposes (applicable at CHUV only)
  • Patients who have signed a consent allowing the use of their residual sample (Restprobenerklärung) (applicable at MUI, only)
  • Patients over the age of 18 years (>18)
  • Patients with bacteremia considered to be due to E. coli or K. pneumoniae
  • Patients whose positive blood cultures were not older than 24 hours at the time of AST start

Who cannot take part

  • Patients with documented refusal of the use of biological material for research purposes (applicable at CHUV, only)
  • Patients with polymicrobial bacteremia

This trial has no sites in United States.

It has sites in 3 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

The aim of this study is to assess the sensitivity, specificity, and accuracy of the Resistell Phenotech device in testing antibiotic susceptibility of Gram-negative bacteria (i.e., E. coli or K. pneumoniae) to clinically relevant antibiotics. The study is designed as a prospective, non-interventional, multi-center, single-arm study.

Read full original descriptionShow less

The blood culture samples from bacteremia patients that are positive for E. coli or K. pneumoniae will be tested with the Resistell Phenotech device after strain identification by MALDI-TOF. The results of the Resistell AST will be compared with the results from the disk diffusion tests (all sites use the Kirby-Bauer disk diffusion test), and site dependent tests (VITEK® 2, BD Phoenix™, MicroScan WalkAway system, and/or EUCAST RAST), which are currently the standard AST methods in the microbiology laboratories at the participating sites.

Treatments tested

  • Resistell Phenotech

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Resistell Phenotech AST to Determine the Antibiotic Susceptibility of Gram-negative Bacteria Causing Bacteremia: a Prospective, Non-interventional, Multi-centric, Clinical Performance Study
Record updated
26 October 2024